The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Zeniya, Moko ^a   Mori, Takayasu ^a   Yui, Naofumi ^a   Nomura, Naohiro ^a   Mandai, Shintaro ^a   Isobe, Kiyoshi ^a   Chiga, Motoko ^a   Sohara, Eisei ^a   Rai, Tatemitsu ^a   Uchida, Shinichi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARISTOLOCHIC ACID; ARISTOLOCHIC ACID I; BORTEZOMIB; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECT; FIBROSIS; KIDNEY; KIDNEY DISEASE; METABOLISM; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ARISTOLOCHIC ACIDS; BORTEZOMIB; DISEASE MODELS, ANIMAL; FIBROSIS; KIDNEY; KIDNEY DISEASES; MICE; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 85031305512     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-13486-x     Document Type: Article

References (44)

1. Duffield, J. S. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 124, 2299-2306, https://doi. org/10. 1172/JCI72267 (2014).
2. Nath, K. A. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20, 1-17 (1992).
3. Striker, G. E., Schainuck, L. I., Cutler, R. E. & Benditt, E. P. Structural-functional correlations in renal disease. I. A method for assaying and classifying histopathologic changes in renal disease. Hum Pathol 1, 615-630 (1970).
4. Risdon, R. A., Sloper, J. C. & De Wardener, H. E. Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet 2, 363-366 (1968).
5. Cohen, C. et al. Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. Kidney Int 88, 1135-1143, https://doi. org/10. 1038/ki. 2015. 201 (2015).
6. Zannetti, B. A. et al. Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment. Am J Hematol 90, 647-652, https://doi. org/10. 1002/ajh. 24035 (2015).
7. Ward, F. et al. Successful use of combined high cut-off haemodialysis and bortezomib for acute kidney injury associated with myeloma cast nephropathy. Ir Med J 105, 148-149 (2012).
8. Dimopoulos, M. A. et al. International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment. J Clin Oncol 34, 1544-1557, https://doi. org/10. 1200/JCO. 2015. 65. 0044 (2016).
9. Koca, S. S. et al. Proteasome inhibition prevents development of experimental dermal fibrosis. Inflammation 35, 810-817, https:// doi. org/10. 1007/s10753-011-9380-y (2012).
10. Saeki, I. et al. Bortezomib induces tumor-specific cell death and growth inhibition in hepatocellular carcinoma and improves liver fibrosis. J Gastroenterol 48, 738-750, https://doi. org/10. 1007/s00535-012-0675-z (2013).
11. Chang, T. P., Poltoratsky, V. & Vancurova, I. Bortezomib inhibits expression of TGF-1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells. J Immunol 194, 2942-2953, https://doi. org/10. 4049/jimmunol. 1402610 (2015).
12. Mutlu, G. M. et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-(1) signalling. Thorax 67, 139-146, https://doi. org/10. 1136/thoraxjnl-2011-200717 (2012).
13. Böttinger, E. P. TGF-beta in renal injury and disease. Semin Nephrol 27, 309-320, https://doi. org/10. 1016/j. semnephrol. 2007. 02. 009 (2007).
14. Yanagita, M. Inhibitors/antagonists of TGF-system in kidney fibrosis. Nephrol Dial Transplant 27, 3686-3691, https://doi. org/10. 1093/ndt/gfs381 (2012).
15. Loeffler, I. & Wolf, G. Transforming growth factor-and the progression of renal disease. Nephrol Dial Transplant 29(Suppl 1), i37-i45, https://doi. org/10. 1093/ndt/gft267 (2014).
16. Yamaguchi, W. et al. Bence-Jones Protein-type Multiple Myeloma Patient Withdrawn from Maintenance Hemodialysis after Longterm Bortezomib and Dexamethasone Therapy. Intern Med 55, 263-268, https://doi. org/10. 2169/internalmedicine. 55. 5310 (2016).
17. Huang, L., Scarpellini, A., Funck, M., Verderio, E. A. & Johnson, T. S. Development of a chronic kidney disease model in C57BL/6 mice with relevance to human pathology. Nephron Extra 3, 12-29, https://doi. org/10. 1159/000346180 (2013).
18. Depierreux, M., Van Damme, B., Vanden Houte, K. & Vanherweghem, J. L. Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis 24, 172-180 (1994).
19. Vanherweghem, J. L. et al. Rapidly progressive interstitial renal fibrosis in young women: Association with slimming regimen including Chinese herbs. Lancet 341, 387-391 (1993).
20. Zhao, Y. Y. et al. Metabolomics analysis reveals the association between lipid abnormalities and oxidative stress, inflammation, fibrosis, and Nrf2 dysfunction in aristolochic acid-induced nephropathy. Sci Rep 5, 12936, https://doi. org/10. 1038/srep12936 (2015).
21. Mishra, J. et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14, 2534-2543 (2003).
22. Ichimura, T. et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273, 4135-4142 (1998).
23. Zhou, L. et al. Mechanism of chronic aristolochic acid nephropathy: role of Smad3. Am J Physiol Renal Physiol 298, F1006-1017, https://doi. org/10. 1152/ajprenal. 00675. 2009 (2010).
24. Qu, X. et al. Regulation of renal fibrosis by Smad3 Thr388 phosphorylation. Am J Pathol 184, 944-952, https://doi. org/10. 1016/j. Ajpath. 2013. 12. 003 (2014).
25. Li, Y. et al. Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med 16, 535-143 (2010).
26. Canaud, G. et al. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dial Transplant 30, 575-83 (2015).
27. Yi-He, L. et al. PS-341, a Novel Proteasome Inhibitor, Induces Bcl-2 Phosphorylation and Cleavage in Association with G2-M Phase Arrest and Apoptosis 1 Supported in part by NIH Grants CA50270 and U01 CA76642. Mol Cancer Ther 1, 841-849 (2002).
28. Sakairi, T. et al. Effects of proteasome inhibitors on rat renal fibrosis in vitro and in vivo. Nephrology (Carlton) 16, 76-86, https://doi. org/10. 1111/j. 1440-1797. 2010. 01367. x (2011).
29. Rapino, F., Naumann, I. & Fulda, S. Bortezomib antagonizes microtubule-interfering drug-induced apoptosis by inhibiting G2/M transition and MCL-1 degradation. Cell Death Dis. 21, e925, https://doi. org/10. 1038/cddis. 2013. 440 (2013).
30. Aminzadeh, M. A., Nicholas, S. B., Norris, K. C. & Vaziri, N. D. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol Dial Transplant 28, 2038-2045, https://doi. org/10. 1093/ ndt/gft022 (2013).
31. Sharma, K. Obesity oxidative stress, and fibrosis in chronic kidney disease. Kidney Int Suppl (2011) 4, 113-117, https://doi. org/10. 1038/kisup. 2014. 21 (2014).
32. Wu, D. T. et al. TGF-beta concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes. J Am Soc Nephrol 16, 3211-21 (2005).
33. Bailey, K. L. et al. TGF/Smad3 regulates proliferation and apoptosis through IRS-1 inhibition in colon cancer cells. PLoS One. 17(12(4)), e0176096, https://doi. org/10. 1371/journal. pone. 0176096 (2017).
34. Fu, P. et al. Signaling mechanism of renal fibrosis in unilateral ureteral obstructive kidney disease in ROCK1 knockout mice. J Am Soc Nephrol 17, 3105-3114, https://doi. org/10. 1681/ASN. 2005121366 (2006).
35. Tashiro, K. et al. Attenuation of renal fibrosis by proteasome inhibition in rat obstructive nephropathy: possible role of nuclear factor kappaB. Int J Mol Med 12, 587-592 (2003).
36. Malik, A. et al. Aristolochic acid induced suicidal erythrocyte death. Kidney Blood Press Res 39, 408-419, https://doi. org/10. 1159/000368454 (2014).
37. Chen, Y. H., Chou, C. Y. & Sun, C. Y. Impairment of the Cellular Distribution and Stability of the Erythropoietin Receptor Through the Direct Targeting of Aristolochic Acid. Toxicol Sci 147, 246-254, https://doi. org/10. 1093/toxsci/kfv125 (2015).
38. Maxwell, P. H. et al. Identification of the renal erythropoietin-producing cells using transgenic mice. Kidney Int 44, 1149-1162 (1993).
39. Asada, N. et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 121, 3981-3990, https://doi. org/10. 1172/JCI57301 (2011).
40. Neubert, K. et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14, 748-755, https://doi. org/10. 1038/nm1763 (2008).
41. Everly, M. J. et al. Bortezomib provides effective therapy for antibody-and cell-mediated acute rejection. Transplantation 86, 1754-1761, https://doi. org/10. 1097/TP. 0b013e318190af83 (2008).
42. Mohty, M., Brissot, E., Savani, B. N. & Gaugler, B. Effects of bortezomib on the immune system: A focus on immune regulation. Biol Blood Marrow Transplant 19, 1416-1420, https://doi. org/10. 1016/j. bbmt. 2013. 05. 011 (2013).
43. Chen, H. et al. Ozone oxidative preconditioning inhibits inflammation and apoptosis in a rat model of renal ischemia/reperfusion injury. Eur J Pharmacol 581, 306-314, https://doi. org/10. 1016/j. ejphar. 2007. 11. 050 (2008).
44. Yang, S. S. et al. SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. J Am Soc Nephrol 21, 1868-1877, https://doi. org/10. 1681/ASN. 2009121295 (2010).